Background/Aims: Bevacizumab (Avastin), an anti-vascular endothelial growth factor drug, has been successfully used in recent years to treat ocular pathologies, mostly by intravitreal administration. The aim of this study was to investigate the safety and efficacy of topically applied bevacizumab for the treatment of neovascular glaucoma (NVG). Methods: Patients with NVG were treated with topical bevacizumab (25 mg/ml) 4 times daily during 2 weeks. The following parameters were evaluated at baseline and on days 3, 7 and 14: visual acuity, slit-lamp examination, intraocular pressure (IOP), heart rate and systemic blood pressure. Iris neovascularization was documented using slit-lamp color photos at baseline and on day 14. Results: Eight eyes of 8 patients with NVG were evaluated. After the 2-week treatment, mean IOP was lowered from 34.9 mm Hg (SD 12.8) at baseline to 28.8 mm Hg (SD 9.9) on day 14, representing a mean reduction of 6.1 mm Hg (17.5%). Three patients had clinical regression of their iris neovascularization. Ocular adverse events were transient and included mild upper eyelid swelling, mild exacerbation of superficial punctate keratitis and mild corneal epithelial bullae in an already edematous cornea. There were no serious systemic adverse events. Conclusions: Topical application of bevacizumab may lower IOP and result in regression of neovascularization in patients with NVG.

Keywords:
Topical bevacizumab, Neovascular glaucoma, Anti-vascular endothelial growth factor
1.
Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adamis AP: Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology 1998;105:232-237.
2.
Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM: Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol 2006;142:1054-1056.
3.
Silva Paula J, Jorge R, Alves Costa R, Rodrigues Mde L, Scott IU: Short-term results of intravitreal bevacizumab (Avastin) on anterior segment neovascularization in neovascular glaucoma. Acta Ophthalmol Scand 2006;84:556-557.
4.
Wakabayashi T, Oshima Y, Sakaguchi H, Ikuno Y, Miki A, Gomi F, et al: Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology 2008;115:1571-1580, 1580.e1-1580.e3.
5.
Yazdani S, Hendi K, Pakravan M, Mahdavi M, Yaseri M: Intravitreal bevacizumab for neovascular glaucoma: a randomized controlled trial. J Glaucoma 2009;18:632-637.
6.
Kotecha A, Spratt A, Ogunbowale L, dell'Omo R, Kulkarni A, Bunce C, et al: Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series. Arch Ophthalmol 2011;129:145-150.
7.
Horsley MB, Kahook MY: Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol 2010;21:112-117.
8.
Mizote M, Baba T, Hirooka K, Yamaji H, Shiraga F: Vascular endothelial growth factor concentrations in aqueous humor before and after subconjunctival injection of bevacizumab for neovascular glaucoma. Jpn J Ophthalmol 2010;54:242-244.
9.
Nomoto H, Shiraga F, Kuno N, Kimura E, Fujii S, Shinomiya K, et al: Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits. Invest Ophthalmol Vis Sci 2009;50:4807-4813.
10.
Yoeruek E, Ziemssen F, Henke-Fahle S, Tatar O, Tura A, Grisanti S, et al: Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn. Acta Ophthalmol 2008;86:322-328.
11.
Waisbourd M, Goldstein M, Loewenstein A: Treatment of diabetic retinopathy with anti-VEGF drugs. Acta Ophthalmol 2011;89:203-207.
12.
Waisbourd M, Loewenstein A: The use of anti-angiogenic drugs for central retinal vein occlusion (in Hebrew). Harefuah 2010;149:243-244, 261.
13.
Waisbourd M, Loewenstein A, Goldstein M, Leibovitch I: Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration. Drugs Aging 2007;24:643-662.
14.
Kahook MY, Schuman JS, Noecker RJ: Intravitreal bevacizumab in a patient with neovascular glaucoma. Ophthalmic Surg Lasers Imaging 2006;37:144-146.
15.
Yazdani S, Hendi K, Pakravan M: Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. J Glaucoma 2007;16:437-439.
16.
Costagliola C, Cipollone U, Rinaldi M, della Corte M, Semeraro F, Romano MR: Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma: a survey on 23 cases throughout 12-month follow-up. Br J Clin Pharmacol 2008;66:667-673.
17.
Duch S, Buchacra O, Milla E, Andreu D, Tellez J: Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J Glaucoma 2009;18:140-143.
18.
Hasanreisoglu M, Weinberger D, Mimouni K, Luski M, Bourla D, Kramer M, et al: Intravitreal bevacizumab as an adjunct treatment for neovascular glaucoma. Eur J Ophthalmol 2009;19:607-612.
19.
Moraczewski AL, Lee RK, Palmberg PF, Rosenfeld PJ, Feuer WJ: Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol 2009;93:589-593.
20.
Jonas JB, Golubkina L, Libondi T, Rensch F: Intravitreal bevacizumab for neovascular glaucoma. Acta Ophthalmol 2010;88:e22-e23.
21.
Sugimoto Y, Mochizuki H, Okumichi H, Takumida M, Takamatsu M, Kawamata S, et al: Effect of intravitreal bevacizumab on iris vessels in neovascular glaucoma patients. Graefes Arch Clin Exp Ophthalmol 2010;248:1601-1609.
22.
Grover S, Gupta S, Sharma R, Brar VS, Chalam KV: Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. Br J Ophthalmol 2009;93:273-274.
23.
Dastjerdi MH, Al-Arfaj KM, Nallasamy N, Hamrah P, Jurkunas UV, Pineda R 2nd, et al: Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. Arch Ophthalmol 2009;127:381-389.
24.
Kim SW, Ha BJ, Kim EK, Tchah H, Kim TI: The effect of topical bevacizumab on corneal neovascularization. Ophthalmology 2008;115:e33-e38.
25.
Koenig Y, Bock F, Horn F, Kruse F, Straub K, Cursiefen C: Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009;247:1375-1382.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.